<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26022660</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>03</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1476-4598</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>14</Volume>
            <PubDate>
              <Year>2015</Year>
              <Month>Apr</Month>
              <Day>17</Day>
            </PubDate>
          </JournalIssue>
          <Title>Molecular cancer</Title>
          <ISOAbbreviation>Mol Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The role of the PI3K/Akt/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses.</ArticleTitle>
        <Pagination>
          <StartPage>87</StartPage>
          <MedlinePgn>87</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">87</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12943-015-0361-x</ELocationID>
        <Abstract>
          <AbstractText>Infection with Human papillomaviruses (HPVs) leads to the development of a wide-range of cancers, accounting for 5% of all human cancers. A prominent example is cervical cancer, one of the leading causes of cancer death in women worldwide. It has been well established that tumor development and progression induced by HPV infection is driven by the sustained expression of two oncogenes E6 and E7. The expression of E6 and E7 not only inhibits the tumor suppressors p53 and Rb, but also alters additional signalling pathways that may be equally important for transformation. Among these pathways, the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signalling cascade plays a very important role in HPV-induced carcinogenesis by acting through multiple cellular and molecular events. In this review, we summarize the frequent amplification of PI3K/Akt/mTOR signals in HPV-induced cancers and discuss how HPV oncogenes E6/E7/E5 activate the PI3K/Akt/mTOR signalling pathway to modulate tumor initiation and progression and affect patient outcome. Improvement of our understanding of the mechanism by which the PI3K/Akt/mTOR signalling pathway contributes to the immortalization and carcinogenesis of HPV-transduced cells will assist in devising novel strategies for preventing and treating HPV-induced cancers.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Lifang</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Molecular Virology and Immunology, Wenzhou Medical University, Wenzhou, 325035 , Zhejiang, PR China. wenzhouzlf@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Jianhong</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Australian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, 37 Kent Street, Woolloongabba, Brisbane, 4102, QLD, Australia. elite53@gmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Current address: Department of Gastric Cancer and Soft Tissue Sarcomas Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, PR China. elite53@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ling</LastName>
            <ForeName>Ming Tat</ForeName>
            <Initials>MT</Initials>
            <AffiliationInfo>
              <Affiliation>Australian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, 37 Kent Street, Woolloongabba, Brisbane, 4102, QLD, Australia. mingtat.ling@qut.edu.au.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Liang</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>The University of Queensland, Brisbane, 4072, QLD, Australia. l.zhao@imb.uq.edu.au.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Kong-Nan</ForeName>
            <Initials>KN</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Molecular Virology and Immunology, Wenzhou Medical University, Wenzhou, 325035 , Zhejiang, PR China. k.zhao@uq.edu.au.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centre for Kidney Disease Research-Venomics Research, The University of Queensland School of Medicine, Translational Research Institute, 37 Kent Street, Woolloongabba, Brisbane, 4102, QLD, Australia. k.zhao@uq.edu.au.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>04</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Mol Cancer</MedlineTA>
        <NlmUniqueID>101147698</NlmUniqueID>
        <ISSNLinking>1476-4598</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.-</RegistryNumber>
          <NameOfSubstance UI="C084025">MAP-kinase-activated kinase 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D064007">Ataxia Telangiectasia Mutated Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="D048051">p38 Mitogen-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064007" MajorTopicYN="N">Ataxia Telangiectasia Mutated Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002472" MajorTopicYN="N">Cell Transformation, Viral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008018" MajorTopicYN="N">Life Cycle Stages</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D027383" MajorTopicYN="N">Papillomaviridae</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D030361" MajorTopicYN="N">Papillomavirus Infections</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048051" MajorTopicYN="N">p38 Mitogen-Activated Protein Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2014</Year>
          <Month>11</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2015</Year>
          <Month>4</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>5</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>5</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>3</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26022660</ArticleId>
        <ArticleId IdType="pmc">PMC4498560</ArticleId>
        <ArticleId IdType="doi">10.1186/s12943-015-0361-x</ArticleId>
        <ArticleId IdType="pii">10.1186/s12943-015-0361-x</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Zhao KN, Chen J. Codon usage roles in human papillomavirus. Rev Med Virol. 2011;21(6):397–411.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22025363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gardiol D, Kuhne C, Glaunsinger B, Lee SS, Javier R, Banks L. Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation. Oncogene. 1999;18(40):5487–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10523825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>zur Hausen H. Viruses in human cancers. Science. 1991;254(5035):1167–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1659743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Talora C, Cialfi S, Segatto O, Morrone S, Kim CJ, Frati L, et al.  Constitutively active Notch1 induces growth arrest of HPV-positive cervical cancer cells via separate signaling pathways. Exp Cell Res. 2005;305(2):343–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15817159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Auvinen E, Crusius K, Steuer B, Alonso A. Human papillomavirus type 16 E5 protein (review) Int J Oncol. 1997;11(6):1297–304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21528338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smola S. Human papillomaviruses and skin cancer. Adv Exp Med Biol. 2014;810:192–207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25207367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel H, Polanco-Echeverry G, Segditsas S, Volikos E, McCart A, Lai C, et al.  Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma. Int J Cancer. 2007;121(12):2668–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17721920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Talora C, Cialfi S, Oliviero C, Palermo R, Pascucci M, Frati L, et al.  Cross talk among Notch3, pre-TCR, and Tal1 in T-cell development and leukemogenesis. Blood. 2006;107(8):3313–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16368887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schiller JT, Lowy DR. Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol. 2012;10(10):681–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6309166</ArticleId>
            <ArticleId IdType="pubmed">22961341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability–an evolving hallmark of cancer. Nat Rev Mol Cell Biol. 2010;11(3):220–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20177397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12044010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duensing S, Münger K. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int J Cancer. 2004;109(2):157–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14750163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomas LK, Bermejo JL, Vinokurova S, Jensen K, Bierkens M, Steenbergen R, et al. Chromosomal gains and losses in human papillomavirus-associated neoplasia of the lower genital tract–a systematic review and meta-analysis. Eur J Cancer. 2013. doi: 10.1016/j.ejca.2013.08.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24054023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler I, Pugh TJ, et al.  Landscape of genomic alterations in cervical carcinomas. Nature. 2014;506(7488):371–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4161954</ArticleId>
            <ArticleId IdType="pubmed">24390348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10(8):550–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20592731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pim D, Massimi P, Dilworth SM, Banks L. Activation of the protein kinase B pathway by the HPV-16 E7 oncoprotein occurs through a mechanism involving interaction with PP2A. Oncogene. 2005;24(53):7830–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16044149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menges CW, Baglia LA, Lapoint R, McCance DJ. Human papillomavirus type 16 E7 up-regulates AKT activity through the retinoblastoma protein. Cancer Res. 2006;66(11):5555–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16740689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tinker AV, Ellard S, Welch S, Moens F, Allo G, Tsao MS, et al.  Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199) Gynecol Oncol. 2013;130(2):269–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23672928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keysar SB, Astling DP, Anderson RT, Vogler BW, Bowles DW, Morton JJ, et al. A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol Oncol. 2013. doi: 10.1016/j.molonc.2013.03.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3760013</ArticleId>
            <ArticleId IdType="pubmed">23607916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma YY, Wei SJ, Lin YC, Lung JC, Chang TC, Whang-Peng J, et al.  PIK3CA as an oncogene in cervical cancer. Oncogene. 2000;19(23):2739–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10851074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bertelsen BI, Steine SJ, Sandvei R, Molven A, Laerum OD. Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation. Int J Cancer. 2006;118(8):1877–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16287065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiosea SI, Grandis JR, Lui VW, Diergaarde B, Maxwell JH, Ferris RL, et al.  PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma. BMC Cancer. 2013;13:602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3878565</ArticleId>
            <ArticleId IdType="pubmed">24341335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, et al.  Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 2013;3(7):761–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3710532</ArticleId>
            <ArticleId IdType="pubmed">23619167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomas SM, Sahu B, Rapireddy S, Bahal R, Wheeler SE, Procopio EM, et al.  Antitumor effects of EGFR antisense guanidine-based peptide nucleic acids in cancer models. ACS Chem Biol. 2013;8(2):345–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3684443</ArticleId>
            <ArticleId IdType="pubmed">23113581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McAuliffe PF, Meric-Bernstam F, Mills GB, Gonzalez-Angulo AM. Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. Clin Breast Cancer. 2010;10(Suppl 3):S59–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21115423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nees M, Geoghegan JM, Hyman T, Frank S, Miller L, Woodworth CD. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J Virol. 2001;75(9):4283–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC114174</ArticleId>
            <ArticleId IdType="pubmed">11287578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J, Chen C, Zhao KN. Phosphatidylinositol 3-kinase signaling as a therapeutic target for cervical cancer. Curr Cancer Drug Targets. 2013;13(2):143–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23297827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stubenrauch F, Laimins LA. Human papillomavirus life cycle: active and latent phases. Semin Cancer Biol. 1999;9(6):379–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10712884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maglennon GA, Doorbar J. The biology of papillomavirus latency. Open Virol J. 2012;6:190–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3547330</ArticleId>
            <ArticleId IdType="pubmed">23341854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moody CA, Laimins LA. Human papillomaviruses activate the ATM DNA damage pathway for viral genome amplification upon differentiation. PLoS Pathog. 2009;5(10)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2745661</ArticleId>
            <ArticleId IdType="pubmed">19798429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doorbar J. Papillomavirus life cycle organization and biomarker selection. Dis Markers. 2007;23(4):297–313.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3851388</ArticleId>
            <ArticleId IdType="pubmed">17627064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oh ST, Longworth MS, Laimins LA. Roles of the E6 and E7 proteins in the life cycle of low-risk human papillomavirus type 11. J Virol. 2004;78(5):2620–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC369251</ArticleId>
            <ArticleId IdType="pubmed">14963169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pyeon D, Pearce SM, Lank SM, Ahlquist P, Lambert PF. Establishment of human papillomavirus infection requires cell cycle progression. PLoS Pathog. 2009;5(2)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2642596</ArticleId>
            <ArticleId IdType="pubmed">19247434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding J, Doorbar J, Li B, Zhou F, Gu W, Zhao L, et al.  Expression of papillomavirus L1 proteins regulated by authentic gene codon usage is favoured in G2/M-like cells in differentiating keratinocytes. Virology. 2010;399(1):46–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20089289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang NX, Gu W, Ding J, Saunders NA, Frazer IH, Zhao KN. Calcium enhances mouse keratinocyte differentiation in vitro to differentially regulate expression of papillomavirus authentic and codon modified L1 genes. Virology. 2007;365(1):187–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17462691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao KN, Gu W, Fang NX, Saunders NA, Frazer IH. Gene codon composition determines differentiation-dependent expression of a viral capsid gene in keratinocytes in vitro and in vivo. Mol Cell Biol. 2005;25(19):8643–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1265747</ArticleId>
            <ArticleId IdType="pubmed">16166644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu W, Ding J, Wang X, de Kluyver RL, Saunders NA, Frazer IH, et al.  Generalized substitution of isoencoding codons shortens the duration of papillomavirus L1 protein expression in transiently gene-transfected keratinocytes due to cell differentiation. Nucleic Acids Res. 2007;35(14):4820–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1950544</ArticleId>
            <ArticleId IdType="pubmed">17621583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev. 2004;68(2):362–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC419925</ArticleId>
            <ArticleId IdType="pubmed">15187189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reinson T, Toots M, Kadaja M, Pipitch R, Allik M, Ustav E, et al.  Engagement of the ATR-dependent DNA damage response at the human papillomavirus 18 replication centers during the initial amplification. J Virol. 2013;87(2):951–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3554080</ArticleId>
            <ArticleId IdType="pubmed">23135710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davy C, Doorbar J. G2/M cell cycle arrest in the life cycle of viruses. Virology. 2007;368(2):219–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7103309</ArticleId>
            <ArticleId IdType="pubmed">17675127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Helt AM, Funk JO, Galloway DA. Inactivation of both the retinoblastoma tumor suppressor and p21 by the human papillomavirus type 16 E7 oncoprotein is necessary to inhibit cell cycle arrest in human epithelial cells. J Virol. 2002;76(20):10559–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC136576</ArticleId>
            <ArticleId IdType="pubmed">12239337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soutoglou E, Misteli T. Activation of the cellular DNA damage response in the absence of DNA lesions. Science. 2008;320(5882):1507–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2575099</ArticleId>
            <ArticleId IdType="pubmed">18483401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Satsuka A, Mehta K, Laimins L. p38MAPK and MK2 pathways are important for the differentiation-dependent human papillomavirus life cycle. J Virol. 2015;89(3):1919–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4300735</ArticleId>
            <ArticleId IdType="pubmed">25410865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fradet-Turcotte A, Moody C, Laimins LA, Archambault J. Nuclear export of human papillomavirus type 31 E1 is regulated by Cdk2 phosphorylation and required for viral genome maintenance. J Virol. 2010;84(22):11747–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2977856</ArticleId>
            <ArticleId IdType="pubmed">20844047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gillespie KA, Mehta KP, Laimins LA, Moody CA. Human papillomaviruses recruit cellular DNA repair and homologous recombination factors to viral replication centers. J Virol. 2012;86(17):9520–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3416172</ArticleId>
            <ArticleId IdType="pubmed">22740399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doorbar J. The papillomavirus life cycle. J Clin Virol. 2005;32(Suppl 1):S7–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15753007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16(1):1–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC145302</ArticleId>
            <ArticleId IdType="pubmed">12525422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lechner M, Frampton GM, Fenton T, Feber A, Palmer G, Jay A, et al.  Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors. Genome Med. 2013;5(5):49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4064312</ArticleId>
            <ArticleId IdType="pubmed">23718828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J, Chen J, Zhang L, Masci PP, Zhao KN. Four major factors regulate phosphatidylinositol 3-kinasesignaling pathway in cancers induced by infection of human Papillomaviruses. Curr Med Chem. 2014;21(26):3057–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24735365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Psyrri A, Seiwert TY, Jimeno A.  American Society of Clinical Oncology educational book / ASCO American Society of Clinical Oncology Meeting. 2013. Molecular pathways in head and neck cancer: EGFR, PI3K, and more; pp. 246–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23714515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Won HS, Jung CK, Chun SH, Kang JH, Kim YS, Sun DI, et al.  Difference in expression of EGFR, pAkt, and PTEN between oropharyngeal and oral cavity squamous cell carcinoma. Oral Oncol. 2012;48(10):985–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22682934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang E, Feng X, Liu F, Zhang P, Liang J, Tang X. Roles of PI3K/Akt and c-Jun signaling pathways in human papillomavirus type 16 oncoprotein-induced HIF-1alpha, VEGF, and IL-8 expression and in vitro angiogenesis in non-small cell lung cancer cells. PLoS One. 2014;9(7)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4110025</ArticleId>
            <ArticleId IdType="pubmed">25058399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murakami S, Sakurai-Yageta M, Maruyama T, Murakami Y. Trans-homophilic interaction of CADM1 activates PI3K by forming a complex with MAGuK-family proteins MPP3 and Dlg. PLoS One. 2014;9(2)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3913574</ArticleId>
            <ArticleId IdType="pubmed">24503895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao R, Cooper GM. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science. 1995;267(5206):2003–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7701324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J, et al.  Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature. 1997;385(6616):544–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9020362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee CM, Fuhrman CB, Planelles V, Peltier MR, Gaffney DK, Soisson AP, et al.  Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines. Clin Cancer Res. 2006;12(1):250–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16397049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang P, Steinberg BM. Overexpression of PTEN/MMAC1 and decreased activation of Akt in human papillomavirus-infected laryngeal papillomas. Cancer Res. 2000;60(5):1457–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10728713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Howie HL, Koop JI, Weese J, Robinson K, Wipf G, Kim L, et al.  Beta-HPV 5 and 8 E6 promote p300 degradation by blocking AKT/p300 association. PLoS Pathog. 2011;7(8)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3161984</ArticleId>
            <ArticleId IdType="pubmed">21901101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X, Mayeda A, Tao M, Zheng ZM. Exonic splicing enhancer-dependent selection of the bovine papillomavirus type 1 nucleotide 3225 3′ splice site can be rescued in a cell lacking splicing factor ASF/SF2 through activation of the phosphatidylinositol 3-kinase/Akt pathway. J Virol. 2003;77(3):2105–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC140879</ArticleId>
            <ArticleId IdType="pubmed">12525645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McFarlane M, Graham SV. Human papillomavirus regulation of SR proteins. Biochem Soc Trans. 2010;38(4):1116–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20659014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang YH, Yu CW, Lai LC, Tsao CH, Ho KT, Yang SC, et al.  Up-regulation of interleukin-17 expression by human papillomavirus type 16 E6 in nonsmall cell lung cancer. Cancer. 2010;116(20):4800–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20578176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kohrenhagen N, Voelker HU, Schmidt M, Kapp M, Krockenberger M, Frambach T, et al.  Expression of transketolase-like 1 (TKTL1) and p-Akt correlates with the progression of cervical neoplasia. J Obstet Gynaecol Res. 2008;34(3):293–300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18686341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faried LS, Faried A, Kanuma T, Sano T, Nakazato T, Tamura T, et al.  Predictive and prognostic role of activated mammalian target of rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy. Oncol Rep. 2006;16(1):57–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16786123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta AK, Lee JH, Wilke WW, Quon H, Smith G, Maity A, et al.  Radiation response in two HPV-infected head-and-neck cancer cell lines in comparison to a non-HPV-infected cell line and relationship to signaling through AKT. Int J Radiat Oncol Biol Phys. 2009;74(3):928–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2766796</ArticleId>
            <ArticleId IdType="pubmed">19480971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henken FE, Banerjee NS, Snijders PJ, Meijer CJ, De-Castro AJ, Rosl F, et al.  PIK3CA-mediated PI3-kinase signalling is essential for HPV-induced transformation in vitro. Mol Cancer. 2011;10:71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3130697</ArticleId>
            <ArticleId IdType="pubmed">21663621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu K, Paik JC, Wang B, Lin FT, Lin WC. Regulation of TopBP1 oligomerization by Akt/PKB for cell survival. Embo J. 2006;25(20):4795–807.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1618094</ArticleId>
            <ArticleId IdType="pubmed">17006541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aoki I, Higuchi M, Gotoh Y. NEDDylation controls the target specificity of E2F1 and apoptosis induction. Oncogene. 2013;32(34):3954–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23001041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dennemarker J, Lohmuller T, Mayerle J, Tacke M, Lerch MM, Coussens LM, et al.  Deficiency for the cysteine protease cathepsin L promotes tumor progression in mouse epidermis. Oncogene. 2010;29(11):1611–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3082505</ArticleId>
            <ArticleId IdType="pubmed">20023699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joyce JA, Baruch A, Chehade K, Meyer-Morse N, Giraudo E, Tsai FY, et al.  Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell. 2004;5(5):443–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15144952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sichtig N, Silling S, Steger G. Papillomavirus binding factor (PBF)-mediated inhibition of cell growth is regulated by 14-3-3beta. Arch Biochem Biophys. 2007;464(1):90–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17531190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsukahara T, Nabeta Y, Kawaguchi S, Ikeda H, Sato Y, Shimozawa K, et al.  Identification of human autologous cytotoxic T-lymphocyte-defined osteosarcoma gene that encodes a transcriptional regulator, papillomavirus binding factor. Cancer Res. 2004;64(15):5442–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15289353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999;13(22):2905–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10579998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sah JF, Balasubramanian S, Eckert RL, Rorke EA. Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases. J Biol Chem. 2004;279(13):12755–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14701854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Shaughnessy RF, Akgul B, Storey A, Pfister H, Harwood CA, Byrne C. Cutaneous human papillomaviruses down-regulate AKT1, whereas AKT2 up-regulation and activation associates with tumors. Cancer Res. 2007;67(17):8207–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2426757</ArticleId>
            <ArticleId IdType="pubmed">17804734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paolini F, Carbone A, Benevolo M, Silipo V, Rollo F, Covello R, et al.  Human Papillomaviruses, p16INK4a and Akt expression in basal cell carcinoma. J Exp Clin Cancer Res. 2011;30:108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3271997</ArticleId>
            <ArticleId IdType="pubmed">22082146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shin MK, Balsitis S, Brake T, Lambert PF. Human papillomavirus E7 oncoprotein overrides the tumor suppressor activity of p21Cip1 in cervical carcinogenesis. Cancer Res. 2009;69(14):5656–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2858290</ArticleId>
            <ArticleId IdType="pubmed">19584294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molinolo AA, Marsh C, El DM, Gangane N, Jennison K, Hewitt S, et al.  mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas. Clin Cancer Res. 2012;18(9):2558–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3443560</ArticleId>
            <ArticleId IdType="pubmed">22409888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishikawa M, Fujii T, Masumoto N, Saito M, Mukai M, Nindl I, et al.  Correlation of p16INK4A overexpression with human papillomavirus infection in cervical adenocarcinomas. Int J Gynecol Pathol. 2003;22(4):378–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14501820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dimri G, Band H, Band V. Mammary epithelial cell transformation: insights from cell culture and mouse models. Breast Cancer Res. 2005;7(4):171–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1175079</ArticleId>
            <ArticleId IdType="pubmed">15987472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Surviladze Z, Sterk RT, Deharo SA, Ozbun MA. Cellular entry of human papillomavirus type 16 involves activation of the phosphatidylinositol 3-Kinase/Akt/mTOR pathway and inhibition of autophagy. J Virol. 2013;87(5):2508–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3571372</ArticleId>
            <ArticleId IdType="pubmed">23255786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sewell A, Brown B, Biktasova A, Mills GB, Lu Y, Tyson DR, et al.  Reverse-phase protein array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer. Clin Cancer Res. 2014;20(9):2300–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4027970</ArticleId>
            <ArticleId IdType="pubmed">24599934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng W, Duan X, Liu J, Xiao J, Brown RE. Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions. Int J Clin Exp Pathol. 2009;2(3):249–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2600462</ArticleId>
            <ArticleId IdType="pubmed">19079619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schilder RJ, Sill MW, Lee YC, Mannel R. A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Int J Gynecol Cancer. 2009;19(5):929–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2722934</ArticleId>
            <ArticleId IdType="pubmed">19574787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coppock JD, Wieking BG, Molinolo AA, Gutkind JS, Miskimins WK, Lee JH. Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition. Neoplasia. 2013;15(6):620–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3664994</ArticleId>
            <ArticleId IdType="pubmed">23730210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park JK, Cho CH, Ramachandran S, Shin SJ, Kwon SH, Kwon SY, et al.  Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3-kinase inhibition in the human cervical cancer cell-line. Cancer Res Treat. 2006;38(2):112–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2741669</ArticleId>
            <ArticleId IdType="pubmed">19771269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DiMaio D, Petti LM. The E5 proteins. Virology. 2013;445(1–2):99–114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3772959</ArticleId>
            <ArticleId IdType="pubmed">23731971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roman A, Munger K. The papillomavirus E7 proteins. Virology. 2013;445(1–2):138–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3783579</ArticleId>
            <ArticleId IdType="pubmed">23731972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vande Pol SB, Klingelhutz AJ. Papillomavirus E6 oncoproteins. Virology. 2013;445(1–2):115–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3783570</ArticleId>
            <ArticleId IdType="pubmed">23711382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Doorslaer K, Burk RD. Evolution of human papillomavirus carcinogenicity. Adv Virus Res. 2010;77:41–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3690501</ArticleId>
            <ArticleId IdType="pubmed">20951869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romanczuk H, Villa LL, Schlegel R, Howley PM. The viral transcriptional regulatory region upstream of the E6 and E7 genes is a major determinant of the differential immortalization activities of human papillomavirus types 16 and 18. J Virol. 1991;65(5):2739–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC240641</ArticleId>
            <ArticleId IdType="pubmed">1850048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamura T, Williams-Simons L, Westphal H. A human papillomavirus type 18 E6/E7 transgene sensitizes mouse lens cells to human wild-type p53-mediated apoptosis. Oncogene. 1997;14(25):2991–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9223662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinez-Cruz AB, Santos M, Lara MF, Segrelles C, Ruiz S, Moral M, et al.  Spontaneous squamous cell carcinoma induced by the somatic inactivation of retinoblastoma and Trp53 tumor suppressors. Cancer Res. 2008;68(3):683–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18245467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang S, Wu X, Jiang T, Lu Y, Ma L, Liang M, et al.  The up-regulation of KCC1 gene expression in cervical cancer cells by IGF-II through the ERK1/2MAPK and PI3K/AKT pathways and its significance. Eur J Gynaecol Oncol. 2009;30(1):29–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19317253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang X, Zhang Q, Nishitani J, Brown J, Shi S, Le AD. Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells. Clin Cancer Res. 2007;13(9):2568–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17473185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hyland PL, McDade SS, McCloskey R, Dickson GJ, Arthur K, McCance DJ, et al.  Evidence for alteration of EZH2, BMI1, and KDM6A and epigenetic reprogramming in human papillomavirus type 16 E6/E7-expressing keratinocytes. J Virol. 2011;85(21):10999–1006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3194988</ArticleId>
            <ArticleId IdType="pubmed">21865393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crook T, Morgenstern JP, Crawford L, Banks L. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. Embo J. 1989;8(2):513–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC400835</ArticleId>
            <ArticleId IdType="pubmed">2542020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cordova-Alarcon E, Centeno F, Reyes-Esparza J, Garcia-Carranca A, Garrido E. Effects of HRAS oncogene on cell cycle progression in a cervical cancer-derived cell line. Arch Med Res. 2005;36(4):311–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15950068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Veeraraghavalu K, Subbaiah VK, Srivastava S, Chakrabarti O, Syal R, Krishna S. Complementation of human papillomavirus type 16 E6 and E7 by Jagged1-specific Notch1-phosphatidylinositol 3-kinase signaling involves pleiotropic oncogenic functions independent of CBF1;Su(H);Lag-1 activation. J Virol. 2005;79(12):7889–98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1143639</ArticleId>
            <ArticleId IdType="pubmed">15919944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whelan RD, Kiley SC, Parker PJ. Tetradecanoyl phorbol acetate-induced microtubule reorganization is required for sustained mitogen-activated protein kinase activation and morphological differentiation of U937 cells. Cell Growth Differ. 1999;10(4):271–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10319997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pim D, Tomaic V, Banks L. The human papillomavirus (HPV) E6* proteins from high-risk, mucosal HPVs can direct degradation of cellular proteins in the absence of full-length E6 protein. J Virol. 2009;83(19):9863–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2748042</ArticleId>
            <ArticleId IdType="pubmed">19640984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lace MJ, Anson JR, Haugen TH, Turek LP. Interferon regulatory factor (IRF)-2 activates the HPV-16 E6-E7 promoter in keratinocytes. Virology. 2010;399(2):270–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20129639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Contreras-Paredes A, De la Cruz-Hernandez E, Martinez-Ramirez I, Duenas-Gonzalez A, Lizano M. E6 variants of human papillomavirus 18 differentially modulate the protein kinase B/phosphatidylinositol 3-kinase (akt/PI3K) signaling pathway. Virology. 2009;383(1):78–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19007961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Accardi R, Rubino R, Scalise M, Gheit T, Shahzad N, Thomas M, et al.  E6 and E7 from human papillomavirus type 16 cooperate to target the PDZ protein Na/H exchange regulatory factor 1. J Virol. 2011;85(16):8208–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3147992</ArticleId>
            <ArticleId IdType="pubmed">21680517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pim D, Collins M, Banks L. Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor. Oncogene. 1992;7(1):27–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1311063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kiyono T, Hiraiwa A, Fujita M, Hayashi Y, Akiyama T, Ishibashi M. Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci U S A. 1997;94(21):11612–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC23554</ArticleId>
            <ArticleId IdType="pubmed">9326658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kranjec C, Massimi P, Banks L. Restoration of MAGI-1 expression in HPV positive tumour cells induces cell growth arrest and apoptosis. J Virol. 2014. doi: 10.1128/JVI.03247-13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4054424</ArticleId>
            <ArticleId IdType="pubmed">24696483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chakrabarti O, Veeraraghavalu K, Tergaonkar V, Liu Y, Androphy EJ, Stanley MA, et al.  Human papillomavirus type 16 E6 amino acid 83 variants enhance E6-mediated MAPK signaling and differentially regulate tumorigenesis by notch signaling and oncogenic Ras. J Virol. 2004;78(11):5934–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC415794</ArticleId>
            <ArticleId IdType="pubmed">15140991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fragoso-Ontiveros V, Maria A-GR, Contreras-Paredes A, Vaca-Paniagua F, Alonso HL, Lopez-Camarillo C, et al.  Gene expression profiles induced by E6 from non-European HPV18 variants reveals a differential activation on cellular processes driving to carcinogenesis. Virology. 2012;432(1):81–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22743128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spangle JM, Ghosh-Choudhury N, Munger K. Activation of cap-dependent translation by mucosal human papillomavirus E6 proteins is dependent on the integrity of the LXXLL binding motif. J Virol. 2012;86(14):7466–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3416298</ArticleId>
            <ArticleId IdType="pubmed">22553330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanier K, Charbonnier S, Sidi AO, McEwen AG, Ferrario MG, Poussin-Courmontagne P, et al.  Structural basis for hijacking of cellular LxxLL motifs by papillomavirus E6 oncoproteins. Science. 2013;339(6120):694–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3899395</ArticleId>
            <ArticleId IdType="pubmed">23393263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brimer N, Lyons C, Wallberg AE, Vande PSB. Cutaneous papillomavirus E6 oncoproteins associate with MAML1 to repress transactivation and NOTCH signaling. Oncogene. 2012;31(43):4639–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3330202</ArticleId>
            <ArticleId IdType="pubmed">22249263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Y, Pan Y, Zhang S, Shi X, Ning T, Ke Y. Increased phosphorylation of p70 S6 kinase is associated with HPV16 infection in cervical cancer and esophageal cancer. Br J Cancer. 2007;97(2):218–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2360306</ArticleId>
            <ArticleId IdType="pubmed">17622239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu Z, Hu X, Li Y, Zheng L, Zhou Y, Jiang H, et al.  Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin. J Biol Chem. 2004;279(34):35664–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15175323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng L, Ding H, Lu Z, Li Y, Pan Y, Ning T, et al.  E3 ubiquitin ligase E6AP-mediated TSC2 turnover in the presence and absence of HPV16 E6. Genes Cells. 2008;13(3):285–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18298802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spangle JM, Munger K. The HPV16 E6 oncoprotein causes prolonged receptor protein tyrosine kinase signaling and enhances internalization of phosphorylated receptor species. PLoS Pathog. 2013;9(3)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3597533</ArticleId>
            <ArticleId IdType="pubmed">23516367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spangle JM, Munger K. The human papillomavirus type 16 E6 oncoprotein activates mTORC1 signaling and increases protein synthesis. J Virol. 2010;84(18):9398–407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2937655</ArticleId>
            <ArticleId IdType="pubmed">20631133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cardone RA, Greco MR, Capulli M, Weinman EJ, Busco G, Bellizzi A, et al.  NHERF1 acts as a molecular switch to program metastatic behavior and organotropism via its PDZ domains. Mol Biol Cell. 2012;23(11):2028–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3364169</ArticleId>
            <ArticleId IdType="pubmed">22496422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu HH, Wu JY, Cheng YW, Chen CY, Lee MC, Goan YG, et al.  cIAP2 upregulated by E6 oncoprotein via epidermal growth factor receptor/phosphatidylinositol 3-kinase/AKT pathway confers resistance to cisplatin in human papillomavirus 16/18-infected lung cancer. Clin Cancer Res. 2010;16(21):5200–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20959404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li L, Ren CH, Tahir SA, Ren C, Thompson TC. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol. 2003;23(24):9389–404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC309640</ArticleId>
            <ArticleId IdType="pubmed">14645548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Charette ST, McCance DJ. The E7 protein from human papillomavirus type 16 enhances keratinocyte migration in an Akt-dependent manner. Oncogene. 2007;26(52):7386–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17533372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thaler S, Hahnel PS, Schad A, Dammann R, Schuler M. RASSF1A mediates p21Cip1/Waf1-dependent cell cycle arrest and senescence through modulation of the Raf-MEK-ERK pathway and inhibition of Akt. Cancer Res. 2009;69(5):1748–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19223555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rorke EA, Zhang D, Choo CK, Eckert RL, Jacobberger JW. TGF-beta-mediated cell cycle arrest of HPV16-immortalized human ectocervical cells correlates with decreased E6/E7 mRNA and increased p53 and p21(WAF-1) expression. Exp Cell Res. 2000;259(1):149–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10942587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Westbrook TF, Nguyen DX, Thrash BR, McCance DJ. E7 abolishes raf-induced arrest via mislocalization of p21(Cip1) Mol Cell Biol. 2002;22(20):7041–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC139800</ArticleId>
            <ArticleId IdType="pubmed">12242284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahn J, Won M, Choi JH, Kim YS, Jung CR, Im DS, et al.  Reactive oxygen species-mediated activation of the Akt/ASK1/p38 signaling cascade and p21(Cip1) downregulation are required for shikonin-induced apoptosis. Apoptosis. 2013;18(7):870–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23546866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zerfass-Thome K, Zwerschke W, Mannhardt B, Tindle R, Botz JW, Jansen-Durr P. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene. 1996;13(11):2323–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8957073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eichten A, Rud DS, Grace M, Piboonniyom SO, Zacny V, Munger K. Molecular pathways executing the “trophic sentinel” response in HPV-16 E7-expressing normal human diploid fibroblasts upon growth factor deprivation. Virology. 2004;319(1):81–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14967490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noh KH, Kang TH, Kim JH, Pai SI, Lin KY, Hung CF, et al.  Activation of Akt as a mechanism for tumor immune evasion. Mol Ther. 2009;17(3):439–47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2835083</ArticleId>
            <ArticleId IdType="pubmed">19107122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan H, Fu F, Zhuo J, Wang W, Nishitani J, An DS, et al.  Human papillomavirus type 16 E6 and E7 oncoproteins upregulate c-IAP2 gene expression and confer resistance to apoptosis. Oncogene. 2005;24(32):5069–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15856013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martelli AM, Tazzari PL, Tabellini G, Bortul R, Billi AM, Manzoli L, et al.  A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. Leukemia. 2003;17(9):1794–805.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12970779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song L, Xiong H, Li J, Liao W, Wang L, Wu J, et al.  Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-kappaB pathway in human non-small cell lung cancer. Clin Cancer Res. 2011;17(7):1839–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21325072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou F, Chen J, Zhao KN. Human papillomavirus 16-encoded E7 protein inhibits IFN-gamma-mediated MHC Class I antigen presentation and CTL-induced lysis through blocking IRF-1 expression in mouse keratinocytes. J Gen Virol 2013. doi: 10.1099/vir.0.054486-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23956301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee JH, Chun T, Park SY, Rho SB. Interferon regulatory factor-1 (IRF-1) regulates VEGF-induced angiogenesis in HUVECs. Biochim Biophys Acta. 2008;1783(9):1654–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18472010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brazil DP, Hemmings BA. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci. 2001;26(11):657–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11701324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marcelo CL, Kim YG, Kaine JL, Voorhees JJ. Stratification, specialization, and proliferation of primary keratinocyte cultures. Evidence of a functioning in vitro epidermal cell system. J Cell Biol. 1978;79(2 Pt 1):356–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2110248</ArticleId>
            <ArticleId IdType="pubmed">721894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Juliandi B, Abematsu M, Nakashima K. Epigenetic regulation in neural stem cell differentiation. Dev Growth Differ. 2010;52(6):493–504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20608952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Giorgi V, Sestini S, Massi D, Ghersetich I, Lotti T. Keratinocyte growth factor receptors. Dermatol Clin. 2007;25(4):477–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17903607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fumagalli I, Dugue D, Bibault JE, Clemenson C, Vozenin MC, Mondini M, et al.  Cytotoxic effect of lapatinib is restricted to human papillomavirus-positive head and neck squamous cell carcinoma cell lines. OncoTargets Ther. 2015;8:335–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4322874</ArticleId>
            <ArticleId IdType="pubmed">25678800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cichon AC, Pickard A, McDade SS, Sharpe DJ, Moran M, James JA, et al.  AKT in stromal fibroblasts controls invasion of epithelial cells. Oncotarget. 2013;4(7):1103–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3759669</ArticleId>
            <ArticleId IdType="pubmed">23867201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SH, Oh JM, No JH, Bang YJ, Juhnn YS, Song YS. Involvement of NF-kappaB and AP-1 in COX-2 upregulation by human papillomavirus 16 E5 oncoprotein. Carcinogenesis. 2009;30(5):753–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19321801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oh JM, Kim SH, Lee YI, Seo M, Kim SY, Song YS, et al.  Human papillomavirus E5 protein induces expression of the EP4 subtype of prostaglandin E2 receptor in cyclic AMP response element-dependent pathways in cervical cancer cells. Carcinogenesis. 2009;30(1):141–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18849297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oh JM, Kim SH, Cho EA, Song YS, Kim WH, Juhnn YS. Human papillomavirus type 16 E5 protein inhibits hydrogen-peroxide-induced apoptosis by stimulating ubiquitin-proteasome-mediated degradation of Bax in human cervical cancer cells. Carcinogenesis. 2010;31(3):402–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20015862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Storey A, Greenfield I, Banks L, Pim D, Crook T, Crawford L, et al.  Lack of immortalizing activity of a human papillomavirus type 16 variant DNA with a mutation in the E2 gene isolated from normal human cervical keratinocytes. Oncogene. 1992;7(3):459–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1312701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramirez dMA, Sarmentero-Estrada J, Belda-Iniesta C, Taron M, Ramirez dMV, Cejas P, et al.  Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol. 2007;8(10):889–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17851129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serewko MM, Popa C, Dahler AL, Smith L, Strutton GM, Coman W, et al.  Alterations in gene expression and activity during squamous cell carcinoma development. Cancer Res. 2002;62(13):3759–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12097286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang B, Spandau DF, Roman A. E5 protein of human papillomavirus type 16 protects human foreskin keratinocytes from UV B-irradiation-induced apoptosis. J Virol. 2002;76(1):220–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC135706</ArticleId>
            <ArticleId IdType="pubmed">11739687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Purpura V, Belleudi F, Caputo S, Torrisi MR. HPV16 E5 and KGFR/FGFR2b interplay in differentiating epithelial cells. Oncotarget. 2013;4(2):192–205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3712566</ArticleId>
            <ArticleId IdType="pubmed">23545251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crusius K, Kaszkin M, Kinzel V, Alonso A. The human papillomavirus type 16 E5 protein modulates phospholipase C-gamma-1 activity and phosphatidyl inositol turnover in mouse fibroblasts. Oncogene. 1999;18(48):6714–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10597278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SH, Juhnn YS, Kang S, Park SW, Sung MW, Bang YJ, et al.  Human papillomavirus 16 E5 up-regulates the expression of vascular endothelial growth factor through the activation of epidermal growth factor receptor, MEK/ ERK1,2 and PI3K/Akt. Cell Mol Life Sci. 2006;63(7–8):930–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16596339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elyaman W, Bassil R, Bradshaw EM, Orent W, Lahoud Y, Zhu B, et al.  Notch receptors and Smad3 signaling cooperate in the induction of interleukin-9-producing T cells. Immunity. 2012;36(4):623–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3572366</ArticleId>
            <ArticleId IdType="pubmed">22503540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kivi N, Greco D, Auvinen P, Auvinen E. Genes involved in cell adhesion, cell motility and mitogenic signaling are altered due to HPV 16 E5 protein expression. Oncogene. 2008;27(18):2532–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17982485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borzacchiello G, Mogavero S, De VG, Roperto S, Della SL, Roperto F. Activated platelet-derived growth factor beta receptor expression, PI3K-AKT pathway molecular analysis, and transforming signals in equine sarcoids. Vet Pathol. 2009;46(4):589–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19276057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corteggio A, Urraro C, Roperto S, Roperto F, Borzacchiello G. Phosphatidylinositol-3-kinase-AKT pathway, phospho-JUN and phospho-JNK expression in spontaneously arising bovine urinary bladder tumours. J Comp Pathol. 2010;143(2–3):173–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20427051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen MM, Potter SJ, Griep AE. Deregulated cell cycle control in lens epithelial cells by expression of inhibitors of tumor suppressor function. Mech Dev. 2002;112(1–2):101–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11850182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fothergill T, McMillan NA. Papillomavirus virus-like particles activate the PI3-kinase pathway via alpha-6 beta-4 integrin upon binding. Virology. 2006;352(2):319–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16781758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schelhaas M, Shah B, Holzer M, Blattmann P, Kuhling L, Day PM, et al.  Entry of human papillomavirus type 16 by actin-dependent, clathrin- and lipid raft-independent endocytosis. PLoS Pathog. 2012;8(4)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3334892</ArticleId>
            <ArticleId IdType="pubmed">22536154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saeed MF, Kolokoltsov AA, Freiberg AN, Holbrook MR, Davey RA. Phosphoinositide-3 kinase-Akt pathway controls cellular entry of Ebola virus. PLoS Pathog. 2008;4(8)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2516934</ArticleId>
            <ArticleId IdType="pubmed">18769720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Butin-Israeli V, Uzi D, Abd-El-Latif M, Pizov G, Eden A, Haviv YS, et al.  DNA-free recombinant SV40 capsids protect mice from acute renal failure by inducing stress response, survival pathway and apoptotic arrest. PLoS One. 2008;3(8)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2515219</ArticleId>
            <ArticleId IdType="pubmed">18714386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fukuda M, Longnecker R. Epstein-Barr virus latent membrane protein 2A mediates transformation through constitutive activation of the Ras/PI3-K/Akt Pathway. J Virol. 2007;81(17):9299–306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1951437</ArticleId>
            <ArticleId IdType="pubmed">17582000</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
